Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

Lignende værker

• Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
  af: Schiopu, Elena, et al.
  Udgivet: (2016)
• Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
  af: Naing, Aung, et al.
  Udgivet: (2019)
• A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
  af: Becerra, Carlos R., et al.
  Udgivet: (2014)
• Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
  af: Haluska, Paul, et al.
  Udgivet: (2014)
• Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
  af: Petri, Michelle, et al.
  Udgivet: (2013)